Search results
Prediction: These 2 Growth Stocks Could Triple By 2030
Motley Fool via Yahoo Finance· 4 days agoHowever, Axsome's innovative days aren't behind it, which may allow the company to continue...
RFK Jr. Explains Why His Voice Sounds Hoarse
MedPage Today· 6 days agoWelcome to Culture Clinic, MedPage Today's collaboration with Northwell Health to offer a healthcare professional's take on the latest viral medical...
Prediction: These 2 Growth Stocks Could Triple By 2030 | The Motley Fool
The Motley Fool· 4 days agoDoing so requires a compound annual growth rate of 20.1%, well above the broader market's historical...
Groundbreaking Data Collection Platform Opens to A | Newswise
Newswise· 1 day agoWEST PALM BEACH, Fla., May 14, 2024 /PRNewswire/ -- Sleep Consortium, in partnership with leading sleep-related patient advocacy organizations, the global patient community, and key industry ...
Citigroup Lowers Axsome Therapeutics (NASDAQ:AXSM) Price Target to $125.00
ETF DAILY NEWS· 6 days agoAxsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective reduced by Citigroup from $127.00 to $125.00 in a research note issued to investors on Tuesday, Benzinga reports.
Mizuho Cuts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $106.00
ETF DAILY NEWS· 4 days agoAxsome Therapeutics (NASDAQ:AXSM – Free Report) had its price target decreased by Mizuho from $109.00 to $106.00 in a research note issued to investors on Wednesday, Benzinga reports. Mizuho ...
HC Wainwright Reiterates Buy Rating for Axsome Therapeutics (NASDAQ:AXSM)
ETF DAILY NEWS· 6 days agoAxsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. Robert W.
Leerink Partnrs Comments on Axsome Therapeutics, Inc.’s FY2026 Earnings (NASDAQ:AXSM)
ETF DAILY NEWS· 6 days agoAxsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) – Research analysts at Leerink Partnrs reduced their FY2026 earnings per share estimates for shares of Axsome Therapeutics in a report released ...
